HYRIMOZ® is an adalimumab biosimilar manufactured by Sandoz Inc. and indicated for the treatment of various inflammatory conditions.

22 нояб. 2023 г. · A facility in Kundl, Austria, will focus on manufacturing penicillin while a plant in Holzkirchen, Germany, will develop new biosimilars.

21 мар. 2023 г. · Sandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023.

21 нояб. 2023 г. · Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care | Sandoz.

Hyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

1 июл. 2023 г. · Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space ; Switzerland

... Hyrimoz, Idacio, Imraldi, Kromeya, Libmyris, Mabura ... manufactured and marketed by Abbott Laboratories after Abbott's acquisition of BASF Pharma.

23 авг. 2023 г. · As its first product, Cordavis has contracted with Sandoz to commercialize and bring to market Hyrimoz ... “Biosimilars are crucial to creating ...

Manufactured by: Sandoz Inc. Princeton, NJ 08540. All third party trademarks are the property of their respective owners. For more information go to www.HYRIMOZ ...

Manufactured by: Sandoz Inc. Princeton, NJ 08540. US License No. 2003. Made in Austria & U.S.A.. This Medication Guide has been approved by the U.S. Food and ...